https://www.theedgemarkets.com/article/eight-hospitals-conduct-phase-3-clinical-trial-covid19-vaccine-—-health-dg?type=malaysia

https://themalaysianreserve.com/2020/12/04/vaccines-hopefuls-attract-interest-on-newsflow/

https://www.google.com.my/amp/s/news.cgtn.com/news/2020-11-25/Sinopharm-applies-to-bring-its-COVID-19-vaccine-to-market--VIiimRueZy/share_amp.html

Soon maybe next week.

https://www.theedgemarkets.com/article/alibabas-cainiao-says-it-talks-chinese-vaccine-makers-over-logistics?type=corporate

https://www.globaltimes.cn/content/1207458.shtml

"Not releasing data does not represent slow progress. Our data is evaluated by relevant departments following strict protocols, and we are in close communication with the WHO," a representative of Sinopharm told the Global Times.

https://www.globaltimes.cn/content/1208808.shtml

Today news

Analysts said the UK and Russia's quick approval for widespread use of vaccine is mainly in response to new outbreaks that may get worse during the coming winter.

China is very likely to introduce its first officially approved vaccine for mass use in December, but whether it would be approved only for limited use is still under discussion, a Beijing-based immunological professor who asks not to be named told the Global Times.

The first vaccines to get approval are likely the inactivated vaccine candidates from either Sinovac or state-owned Sinopharm, said the professor, noting that other frontrunner candidates such as recombinant adenovirus vector vaccine would be slightly behind or approved for emergency use first.

After lunch TP 0.25

This counter has so much potential, based on the news and research done .

Those investors who acquired the private placement definitely has reasons to do so .

This is just a small hiccups.

https://www.theedgemarkets.com/article/moh-receive-covid19-vaccine-phase-3-clinical-study-next-week

https://www.theedgemarkets.com/article/70-target-covid19-vaccination-malaysia-will-focus-adult-group-—-khairy

I not sure why @ KLBullTrader and @aiyooo are so negative in every post.
If you dislike this counter please move on.

Everyone here is just trying to get some news, and guys you all are

1) Not helping by contributing

2) Based on your past comment, even at other counter are just negative
and harsh words, and also not helping

3) Even though we have the facts, MOU agreement vaccine, source from
reliable source ( The Edge News, Bursa Announcement), you guys still
barking around . NOT HELPING

When the shares turn GREEN you guys say buy buy .

You guys have no shame?

Bloody keyboard warriors

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=107445&name=EA_GA_ATTACHMENTS

3. SALIENT TERMS OF THE AGREEMENT

3.2 Sinopharm Hunan Changde hereby agrees to grant Kanger the priority right of purchase of the
Products whereby in the event there are multiple purchasers who desire to purchase the Products
from Sinopharm Hunan Changde, subject always to the same terms and conditions, Sinopharm
Hunan Changde shall always fulfil and give priority to meet the purchase order of Kanger
before other purchasers

https://www.theedgemarkets.com/article/covid19-rhb-says-vaccine-deployment-could-generate-demand-18-billion-pieces-gloves-year ****

If you realized Kanger's glove production is also commencing at Q1 2021, according to the edge.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3099656

PDF file

RATIONALE
On September 29, 2020, in a filing with Bursa Malaysia (ref no. GA1-29092020-00043),
Kanger announced that it has entered into a collaboration agreement with Sinopharm Group
Hunan Changde Medical Co Ltd (“SGHC”) relating to the distribution of Covid-19 vaccines and
medical equipment products in Malaysia. The Covid-19 vaccines are developed by state-owned
China National Pharmaceutical Group Corp (“Sinopharm”). Sinopharm is the largest and oldest
biotech company in China and currently has Covid-19 vaccines under Phase 3 trials. The
collaboration agreement is valid until September 24, 2023.

SALIENT TERMS OF THE MOU
With this MOU, Kanger will collaborate with ZP to facilitate the import, warehousing, and
distribution of Covid-19 vaccines in Malaysia.
Sinopharm will export/ship the Covid-19 vaccines to Malaysia. Services required from ZP are
importation upon arrival, warehousing, inventory management, pick, pack, delivery to
customers, collection & credit risk assumption. Both Parties agree to discuss other services
required, if any.
Kanger will coordinate with SGHC to facilitate the availability of the Covid-19 vaccines and
will advise ZP accordingly. Kanger will also liaise with the authorities in Malaysia and provide
sales and marketing services.

https://www.theedgemarkets.com/article/moh-gavi-finalising-date-signing-covax-agreement

@KLBullTrader Just yesterday you commented "NPRA is jerung dog, barking news all the way to cheat ppl" and now today you bought in. You really are the hypocrite of the highest order! Shameless!! LOL

HAHAHA I KNOW RIGHT

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3099656


On September 29, 2020, in a filing with Bursa Malaysia (ref no. GA1-29092020-00043),
Kanger announced that it has entered into a collaboration agreement with Sinopharm Group
Hunan Changde Medical Co Ltd (“SGHC”) relating to the distribution of Covid-19 vaccines and
medical equipment products in Malaysia. The Covid-19 vaccines are developed by state-owned
China National Pharmaceutical Group Corp (“Sinopharm”). Sinopharm is the largest and oldest
biotech company in China and currently has Covid-19 vaccines under Phase 3 trials. The
collaboration agreement is valid until September 24, 2023.


If its a con , why does it has a black and white on the company bursa announcement?

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3099656